Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programm...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 38; číslo 14; s. 1505
Hlavní autoři:	Gadgeel, Shirish, Rodríguez-Abreu, Delvys, Speranza, Giovanna, Esteban, Emilio, Felip, Enriqueta, Dómine, Manuel, Hui, Rina, Hochmair, Maximilian J, Clingan, Philip, Powell, Steven F, Cheng, Susanna Yee-Shan, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Garon, Edward B, Novello, Silvia, Rubio-Viqueira, Belén, Boyer, Michael, Kurata, Takayasu, Gray, Jhanelle E, Yang, Jing, Bas, Tuba, Pietanza, M Catherine, Garassino, Marina C
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 10.05.2020
Témata:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Disease-Free Survival Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Middle Aged Neoplasm Metastasis Pemetrexed - pharmacology Pemetrexed - therapeutic use Platinum - pharmacology Platinum - therapeutic use
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!